SCHEMBL6807955

SCHEMBL6807955

NNc1cccc2c1C(=O)c1cccc(Cl)c1C2=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.47
MAPT P10636 1/20 0.47
PABPC1 P11940 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ADORA2A P29274 2/20 0.43
NSD2 O96028 2/20 0.43
MAOA P21397 2/20 0.42
CASP3 P42574 1/20 0.40
TERT O14746 1/20 0.39
FGB P02675 1/20 0.39
MMP14 P50281 1/20 0.39
P2RY4 P51582 1/20 0.38
DHODH Q02127 2/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8265768 0.89 ADORA2A (0.41) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL8204670 0.89 MAPT (0.57) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL3087928 0.83 MAPK1 (0.67) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL125609 0.82 NSD2 (0.55) MAPTMAPK1SMN1; SMN2TDP1ADORA2A
SCHEMBL5573806 0.82 EGFR (0.71) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4123519 0.79 MAPT (0.56) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL7193552 0.77 MAOA (0.74) SMN1; SMN2MAOACASP3TERT
SCHEMBL9846483 0.77 MAOA (0.74) SMN1; SMN2MAOACASP3TERT
Anthraquinone SCHEMBL5172785 0.77 ADORA2A (0.57) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL1476410 0.77 ADORA2A (0.57) MAPTMAPK1SMN1; SMN2TDP1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824998-B2 FOR DETERMINATION IN MAMMALS VIA 1-ANTHRAQUINONYLHYDRAZIDE WITH P-ANIALDEHYDE; DRUG SCREENING; PACKAGING; KITS UNIVERSITY OF IOWA RESEARCH FOUNDATION 2004-11-30 US disclosed
US-20040185520-A1 Compounds and methods for detecting tripeptidyl protease I AKRION, INC. 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040185520-A1 Compounds and methods for detecting tripeptidyl protease I TPP1, DNPEP, TPP2 EGFR 4376/4885MAPT 4541/4885PABPC1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.